Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. - Mai EK; Nogai A; Lokhorst HM; van der Holt B; Zweegman S; Weisel KC; Croockewit S; Jauch A; Hillengass J; Stevens-Kroef M; Raab MS; Broijl A; et al. (HemaSphere, 2024)